FDA Review Should Be More Like Business Negotiation, Orexigen CEO Says
Having seen the “worst of ambiguity and then the greatest of clarity” from FDA, Mike Narachi concludes that “what’s lacking in the U.S. review process is leadership and decision-making that’s transparent to the sponsor.”
You may also be interested in...
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
Next PrecisionFDA challenge aims to detect ‘adverse event anomalies’ including manufacturer-specific patterns and drug-drug interactions.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.